Ketone 101: Monitoring, Management & DKA Risk Across Populations
Live Webinar

This webinar brings together four expert health care professionals to examine the role of ketone monitoring and management as a critical safety strategy in outpatient diabetes care. The session focuses on early identification and response to elevated ketones to help prevent diabetic ketoacidosis (DKA) and support timely clinical decision‑making. 
Overview

This webinar brings together four expert health care professionals to examine the role of ketone monitoring and management as a critical safety strategy in outpatient diabetes care. The session focuses on early identification and response to elevated ketones to help prevent diabetic ketoacidosis (DKA) and support timely clinical decision‑making. 

Attendees will gain practical, real‑world guidance on ketone monitoring and management across diabetes populations, including people living with type 1 diabetes, type 2 diabetes, and diabetes during pregnancy. The session equips participants with strategies to identify elevated ketones early, interpret results, and take appropriate outpatient actions to reduce DKA risk. Content is grounded in current evidence and clinical guidance, including key highlights from the June 2024 ADA Consensus Report on hyperglycemic crises, and emphasizes actionable approaches to support safer care and improved patient outcomes. 

Learning Objectives

After completing this webinar, participants will be able to: 

  • Identify clinical situations and risk factors for ketone production and diabetic ketoacidosis (DKA) across populations, including type 1 diabetes, type 2 diabetes, and diabetes during pregnancy.  
  • Recognize key indicators, factors, and ketone level ranges associated with increased DKA risk.  
  • Recognize appropriate outpatient approaches to ketone monitoring and early response to elevated ketones to reduce the risk of DKA.  
Faculty

Eden M. Miller, DO, D-ACD, D-ABOM 

Chief Executive Officer 

Diabetes and Obesity Care 

Bend, Oregon 

Dr. Eden M. Miller has cultivated a special interest in diabetes, after contracting type-1 diabetes while in medical school. Out of that personal experience, her practice has extended into a subspecialty in diabetes care.    

An impassioned speaker, Her adage for care is that she “only succeeds as a provider if she turns patients into experts on their own disease.” 

Dr. Miller believes that a “physiologic patient individualized approach to diabetes intervention is crucial to success."

She feels if our nation is to triumph over the ravages of diabetes, a collaborative effort; unhindered by fear of personal scrutiny, and barriers for effective treatment need to be removed.”

David M. Maahs, MD, PhD 

Professor of Pediatrics 

Stanford University 

Dr. David M. Maahs is the Lucile Salter Packard Professor of Pediatrics at Stanford University where he is the Division Chief of Pediatric Endocrinology, Associate Chair for Academic Affairs in Pediatrics and Associate Dean for Academic Affairs in the School of Medicine. He is the Associate Director of the Stanford Diabetes Research Center and Past-President of the International Society of Pediatric and Adolescent Diabetes (ISPAD) and has served as Editor-in-Chief of the ISPAD Guidelines and on the ADA Professional Practice Committee.

David C. Klonoff, MD, FACP 

Clinical Professor of Medicine 

University of California, San Francisco

Dr. David C. Klonoff is an endocrinologist specializing in diabetes technology. He serves as Medical Director of the Diabetes Research Institute at Mills-Peninsula Medical Center and is a Clinical Professor of Medicine at the University of California, San Francisco. Dr. Klonoff has led numerous clinical trials and authored more than 400 publications in diabetes technology and care. He is the founding Editor-in-Chief of the Journal of Diabetes Science and Technology and a recognized leader in advancing innovation, standards, and digital health in diabetes.

Celeste P. Durnwald, MD 

Professor, OB/GYN, University of Pennsylvania 

Director, Penn Perinatal Diabetes Program

Dr. Celeste P. Durnwald is a Professor of Obstetrics and Gynecology in the Division of Maternal-Fetal Medicine at the University of Pennsylvania. She serves as Director of the Perinatal Diabetes Program and High-Risk Services at the Helen O. Dickens Center for Women’s Health, and as Program Director of the MFM fellowship. Dr. Durnwald has led multicenter clinical trials and research focused on diabetes in pregnancy and diabetes technology, and has contributed to advisory boards shaping clinical guidelines and care models for pregnant individuals with diabetes. 

Summary
Availability:
Registration Required
Expires on Jul 21, 2027
Location:
Online Meeting
Date / Time:
Jul 21, 2026 2:00 PM - 3:00 PM ET
Cost:
FREE
Credit Offered:
No Credit Offered
Android App Download IOS App Download Powered By